The Selective Toxicity of 1-methyl-4-phenylpyridinium to Dopaminergic Neurons: the Role of Mitochondrial Complex I and Reactive Oxygen Species Revisited
Overview
Pharmacology
Affiliations
1-Methyl-4-phenylpyridinium (MPP(+)) is selectively toxic to dopaminergic neurons and has been studied extensively as an etiologic model of Parkinson's disease (PD) because mitochondrial dysfunction is implicated in both MPP(+) toxicity and the pathogenesis of PD. MPP(+) can inhibit mitochondrial complex I activity, and its toxicity has been attributed to the subsequent mitochondrial depolarization and generation of reactive oxygen species. However, MPP(+) toxicity has also been noted to be greater than predicted by its effect on complex I inhibition or reactive oxygen species generation. Therefore, we examined the effects of MPP(+) on survival, mitochondrial membrane potential (DeltaPsim), and superoxide and reduced glutathione levels in individual dopaminergic and nondopaminergic mesencephalic neurons. MPP(+) (5 microM) selectively induced death in fetal rat dopaminergic neurons and caused a small decrease in their DeltaPsim. In contrast, the specific complex I inhibitor rotenone, at a dose (20 nM) that was less toxic than MPP(+) to dopaminergic neurons, depolarized DeltaPsim to a greater extent than MPP(+). In addition, neither rotenone nor MPP(+) increased superoxide in dopaminergic neurons, and MPP(+) failed to alter levels of reduced glutathione. Therefore, we conclude that increased superoxide and loss of DeltaPsim may not represent primary events in MPP(+) toxicity, and complex I inhibition alone is not sufficient to explain the selective toxicity of MPP(+) to dopaminergic neurons. Clarifying the effects of MPP(+) on energy metabolism may provide insight into the mechanism of dopaminergic neuronal degeneration in PD.
The potential role of CGRP in synuclein-associated neurodegenerative disorders.
Alexoudi A, Donadio V, Karageorgiou E Front Neurosci. 2024; 18:1479830.
PMID: 39568667 PMC: 11576422. DOI: 10.3389/fnins.2024.1479830.
Gonzalez-Alcocer A, Duarte-Jurado A, Soto-Dominguez A, Loera-Arias M, Villarreal-Silva E, Saucedo-Cardenas O Int J Mol Sci. 2023; 24(2).
PMID: 36674772 PMC: 9867532. DOI: 10.3390/ijms24021256.
Ranganayaki S, Jamshidi N, Aiyaz M, Rashmi S, Gayathri N, Harsha P Sci Rep. 2021; 11(1):1483.
PMID: 33452321 PMC: 7810707. DOI: 10.1038/s41598-020-79339-2.
miR-30b protects nigrostriatal dopaminergic neurons from MPP(+)-induced neurotoxicity via SNCA.
Shen Y, Zhu Z, Qian S, Xu C, Wang Y Brain Behav. 2020; 10(4):e01567.
PMID: 32154657 PMC: 7177592. DOI: 10.1002/brb3.1567.
Han Y, Lee J, Lee S Mar Drugs. 2019; 17(9).
PMID: 31480724 PMC: 6780744. DOI: 10.3390/md17090518.